Marina Biotech announced last week that it has non-exclusively licensed its conformationally restricted nucleotide technology to Novartis for $1 million in upfront fees.
CRNs are essentially nucleotide analogs to which the C2' and C4' carbon bonds of the ribose ring are linked, which promotes increased hybridization affinity, according to Marina.
Additional terms of the deal were not disclosed.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
